Loading...
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Middleton, G Silcocks, P Cox, T Valle, Juan W Wadsley, J Propper, D Coxon, F Ross, P Madhusudan, S Roques, T
Middleton, G
Silcocks, P
Cox, T
Valle, Juan W
Wadsley, J
Propper, D
Coxon, F
Ross, P
Madhusudan, S
Roques, T
Citations
Altmetric:
Abstract
We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.
Authors
Middleton, G
Silcocks, P
Cox, T
Valle, Juan W
Wadsley, J
Propper, D
Coxon, F
Ross, P
Madhusudan, S
Roques, T
Cunningham, D
Falk, S
Wadd, N
Harrison, M
Corrie, Pippa
Iveson, Tim
Robinson, A
McAdam, K
Eatock, M
Evans, J
Archer, C
Hickish, T
Garcia-Alonso, A
Nicolson, M
Steward, W
Anthoney, A
Greenhalf, W
Shaw, V
Costello, E
Naisbitt, D
Rawcliffe, C
Nanson, G
Neoptolemos, J
Silcocks, P
Cox, T
Valle, Juan W
Wadsley, J
Propper, D
Coxon, F
Ross, P
Madhusudan, S
Roques, T
Cunningham, D
Falk, S
Wadd, N
Harrison, M
Corrie, Pippa
Iveson, Tim
Robinson, A
McAdam, K
Eatock, M
Evans, J
Archer, C
Hickish, T
Garcia-Alonso, A
Nicolson, M
Steward, W
Anthoney, A
Greenhalf, W
Shaw, V
Costello, E
Naisbitt, D
Rawcliffe, C
Nanson, G
Neoptolemos, J
Description
Date
2014-07
Publisher
Collections
Keywords
Type
Article
Citation
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. 2014, 15 (8):829-40 Lancet Oncol